TriSalus Life Sciences, Inc. (TLSI) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

13/25

Growth 4 Margin 4 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

13
Trifalus Life Sciences (TLSI) Q2 2026: G-Code Reimbursement Expands Addressable Market by $2.5B
August 07, 2026
13
Trisalis Life Sciences (TLSI) Q1 2026: PEDD Study Delivers $7,700 Per Patient Cost Avoidance, Driving Platform Validation
May 13, 2026
16
TLSI Q4 2025: 60% Revenue Surge Supports Strategic Commercial Expansion
March 05, 2026
16
Trisalis Life Sciences (TLSI) Q3 2025: Mapping Drives 30% of Growth as TriNav Platform Broadens Clinical Reach
November 14, 2025
14
Trisalis Life Sciences (TLSI) Q2 2025: TriNavFlex Launch Fuels 52% Revenue Surge and Expands Clinical Reach
August 12, 2025
17
TriSalus Life Sciences (TLSI) Q1 2025: 42% Revenue Growth Driven by PEDD Platform Expansion Amid Strategic Investment
May 15, 2025
15
TriSalus Life Sciences (TLSI) Q4 2024: 59% Revenue Growth Drives Path to EBITDA Positivity
March 27, 2025

Browse all companies